AIDX 20/20 Biolabs (AIDX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-testing laboratories · CIK 0001139685

Quote by TradingView

SEC filings

Insider buyers, 180 days

House members buying, 1 year

STOCK Act, US House only, disclosed up to 45 days after the trade

Funds added, last quarter

13F, latest reported quarter

AIDX filings, in plain words

Read the full summary

The latest 5% ownership filing is a 13D by Jonathan M Cohen, filed 2026-03-10, for 16.8% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

20/20 Biolabs insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for 20/20 Biolabs, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider

Filed

Value

Since filing

no insider purchases or sales on record

0 transactions on record

See all insider buying · insider selling

Seven facts, ranked against the sector · Rank is not a forecast

Insiders

no insider buys or sells on file

Congress

no House purchase disclosed in the last 12 months

Funds

12 funds bought in last quarter

below 79% of Pharma & Biotech

Revenue

+16.7% year over year

more than 64% of Pharma & Biotech

Margin

-182.8% net margin

below 64% of Pharma & Biotech

Buybacks

no share repurchases reported

Short interest

0.4% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30

below 82% of Pharma & Biotech

What changed in the last 30 days

Nothing new filed in the last 30 days

Watch AIDX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it

Total return over 12 months. Each marker is a filing; hover or tap one for the detail.

-99.0%12M

13D/G stake

Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AIDX: institutional holders (13F)

13F holdings, latest reported quarter

Cresset Asset Management, LLC

240,122 sh

$132.0K

VANGUARD FIDUCIARY TRUST CO

52,087 sh

$28.6K

GEODE CAPITAL MANAGEMENT, LLC

49,141 sh

$27.0K

Atlantic Union Bankshares Corp

35,099 sh

$19.3K

VANGUARD CAPITAL MANAGEMENT LLC

24,530 sh

$13.5K

Congress trades in AIDX

No Congress trades reported

No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive

Jonathan M Cohen

Activist 13D · 2026-03-10

16.8%

AIDX planned insider sales (Form 144)

No planned-sale notices

No insider has filed to sell. Watch this after a run-up.

AIDX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).

Fidelity Nasdaq Composite Index Fund

$4.6K position · as of 2026-05-31

0.0%

SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio

Live price

Daily candles from TradingView, under their licence. No filings marked.

Show the live price chart

Why this name is on the desk

The complete filing record, in one place.

The record shows 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector by SEC SIC code

UTHR CPIX MRNA REGN LLY ALNY MDGL CITR DNA VRTX NUVL TWST

AIDX financials

Revenue growth

+16.7%

XBRL, annual

Net margin

-182.8%

Fundamentals

Annual figures from XBRL filings. Pick a past date to see them as known then.

	2025-12	2024-12
Revenue	$2.0M	$1.8M
Gross profit	$604.5K	$360.3K
Operating income	-$3.3M	-$5.7M
Net income	-$3.7M	-$5.6M
EPS (diluted)	-0.76	-1.16
Operating cash flow	-$1.9M	-$2.6M
Cash	$1.0M	$1.8M

SEC XBRL, fiscal years, as known on 2026-10-28

AIDX Stock Sonar score 3/7 axes

Find similar shapes Compare

AIDX ranks highest on risk and compliance (87th percentile) and growth (64th), and lowest on institutional and government (21st), among Pharma & Biotech peers.

Growth

Inputs

Revenue growth, YoY+16.7% · 64 pct, sector of 505
Backlog growth, YoYno backlog line filed, or no year-earlier backlog

Institutional and government

Inputs

Funds adding, latest quarter12 · 21 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters

Risk and compliance

Inputs

Short interest, % of float+0.4% · 87 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)

4 not measured: Profitability, Financial health, Insider conviction, US patents

Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing

Insider buying Insider selling Congress stock trades Activist 13D stakes Form 144 planned sales CEO pay vs performance All companies